The company funds research and development opportunities for therapies of rare diseases, aiming to improve the quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases. It also aims to accelerate the expansion of the Chiesi network in the U.S. among universities, venture capital investors, rare disease patient organizations, and entrepreneurial companies developing treatments for rare diseases.